These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16768123)

  • 1. [Drug therapy for non-alcoholic steatohepatitis].
    Tomita K; Hibi T
    Nihon Rinsho; 2006 Jun; 64(6):1146-51. PubMed ID: 16768123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacological treatment of nonalcoholic fatty liver.
    Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
    Curr Med Chem; 2006; 13(24):2889-900. PubMed ID: 17073635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease and lipids.
    Wierzbicki AS; Oben J
    Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Candidate drugs for non-alcoholic steatohepatitis (NASH)].
    Terai S; Matsumoto T; Sakaida I
    Nihon Yakurigaku Zasshi; 2007 Apr; 129(4):271-5. PubMed ID: 17435339
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of insulin sensitizers in NASH.
    Khashab M; Chalasani N
    Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
    Musso G; Anty R; Petta S
    Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for non-alcoholic steatohepatitis.
    Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment regimens for non-alcoholic fatty liver disease.
    Lam BP; Younossi ZM
    Ann Hepatol; 2009; 8 Suppl 1():S51-9. PubMed ID: 19381125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
    Nseir W; Mograbi J; Ghali M
    Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alcoholic and non-alcoholic steatohepatitis].
    Dufour JF; Oneta CM
    Ther Umsch; 2004 Aug; 61(8):505-12. PubMed ID: 15457967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nonalcoholic steatohepatitis].
    Ratziu V; Tahiri M; Bonyhay L
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S71-80. PubMed ID: 15959406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
    Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
    Tang JT; Mao YM
    J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of medications for the management of patients with NAFLD.
    Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
    Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.